Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT06318871
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This early-phase study tests whether a new immune cell therapy called CIML NK cells, combined with a low dose of IL-2, is safe and feasible for people with advanced kidney or bladder cancers. The therapy uses a patient's own immune cells that are trained in a lab to better recognize and attack cancer. Only 5 participants are enrolled, and the main goal is to see if the treatment can be successfully prepared and given.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.